Category: Australia & Regulation
TGA decisions, scheduling, advertising rules, safety communications and Australian therapeutic-goods policy.
Mounjaro and Eye Disorders in Australia: NAION Warning Explained (2026)
Australian evidence guide to Mounjaro, tirzepatide and NAION: what the TGA warning says, what 10 reports can and cannot establish, and why semaglutide evidence differs.
Read analysis →Ozempic vs Wegovy Australia (2026): TGA Approval and PBS Differences
Short answer (checked 7 October 2026): Ozempic and Wegovy both contain semaglutide, but they are not the same Australian regulatory or PBS proposition. The TGA describes…
Read analysis →Compounded GLP-1 Australia (2026): What the TGA Rules Actually Say
Current Australian answer (checked 7 October 2026): Australian pharmacists must not compound medicines containing GLP-1 receptor agonist analogues. The prohibition took effect on 1 October 2024.…
Read analysis →GLP-1 Safety Warnings Australia (2026): TGA Updates Explained
Source-checked 7 October 2026: Australia’s TGA has updated warnings for GLP-1 receptor agonists and the dual GIP/GLP-1 medicine tirzepatide across several distinct issues: aspiration around general…
Read analysis →Wegovy PBS Australia (2026): Is Semaglutide Listed Yet?
Current answer (checked 7 October 2026): Wegovy is TGA-approved in Australia for chronic weight management, and PBAC recommended a restricted PBS listing for a defined group…
Read analysis →Mounjaro PBS Australia 2026: Listing Status & Negotiations
Current answer — checked 8 October 2026: Mounjaro (tirzepatide) is TGA-approved in Australia for type 2 diabetes and chronic weight management, but it is not currently…
Read analysis →Peptide Lab Tests vs TGA Approval: What Each Proves in Australia
A passing peptide lab result is not TGA approval. Learn how CoAs, HPLC, mass spectrometry, sterility, GMP, ARTG inclusion and lawful access differ in Australia.
Read analysis →TGA vs ARTG vs PBAC vs PBS: How Australian Medicine Approval and Subsidy Differ
A practical Australian guide to four commonly confused medicine-status questions: TGA assessment, ARTG inclusion, PBAC recommendations and PBS subsidy.
Read analysis →GLP-1 Medicines in Australia (2026): TGA Approval, PBS Access and Safety Updates
A dated, source-linked guide to GLP-1 medicines in Australia: TGA-approved indications, PBS access, Wegovy’s listing status and 2026 safety updates.
Read analysis →TB-500 Australia: Schedule 4, Human Evidence, FDA Review and WADA Rules
What TB-500 is, how it differs from full-length thymosin beta-4, what Australian Schedule 4 status means, and why human healing claims remain uncertain.
Read analysis →